Xeligekimab improved enthesitis at Achilles tendon sites in patients with radiographic axial spondyloarthritis: 48-week results of a phase III randomized controlled trial (EULAR 2026) - Mar 18, 2026 - Abstract #POS1340; B.1962; L219; Pres time: Jun 6, 2026; 10:15 AM - 11:15 AM; Location: Poster View; P3 | "After data from xeligekimab-treated patients were pooled (n=189), xeligekimab-treated group demonstrated significant improvement in enthesitis at Achilles tendon sites compared to placebo at both week 16 (mean change: -0.15 [95% CI: -0.20, -0.11] vs. -0.12 [95% CI: -0.19, -0.06]; p < 0.05) and week 48 (mean change: -0.15 [95% CI: -0.20, -0.11] vs. -0.13 [95% CI: -0.20, -0.07]; p < 0.05) (Table 2). Conclusions Xeligekimab provides significant and sustained therapeutic benefit for enthesitis at Achilles tendon sites in patients with active r-axSpA throughout treatment period."
Clinical • P3 data • Ankylosing Spondylitis • Immunology • Inflammatory Arthritis • Seronegative Spondyloarthropathies • Spondylarthritis • IL17A
|
|
Hongsheng Sun1; Naiwen Hu1; Na Zhao1; Xia Wang1; Jin Cao1; Liguo Yin1; Jing Chen1; Jie Liu1; Dongxia Liu1
|